Perspective Therapeutics (NYSEAMERICAN:CATX) Issues Earnings Results

Posted by Francis Steltz on Aug 10th, 2026

Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.05, FiscalAI reports. The firm had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.09 million. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%.

Perspective Therapeutics Price Performance

Shares of CATX remained flat at $3.00 during trading hours on Monday. 912,715 shares of the stock traded hands, compared to its average volume of 2,355,088. Perspective Therapeutics has a 52 week low of $1.96 and a 52 week high of $6.16. The business’s fifty day simple moving average is $3.11 and its 200-day simple moving average is $3.93.

Institutional Trading of Perspective Therapeutics

A number of institutional investors have recently bought and sold shares of CATX. Deutsche Bank AG grew its stake in Perspective Therapeutics by 6.1% in the fourth quarter. Deutsche Bank AG now owns 54,245 shares of the company’s stock valued at $149,000 after acquiring an additional 3,119 shares during the period. Vontobel Holding Ltd. raised its position in shares of Perspective Therapeutics by 25.0% during the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock worth $69,000 after purchasing an additional 5,000 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Perspective Therapeutics by 184.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after purchasing an additional 5,475 shares in the last quarter. Barclays PLC lifted its holdings in shares of Perspective Therapeutics by 10.7% in the 4th quarter. Barclays PLC now owns 92,791 shares of the company’s stock worth $255,000 after purchasing an additional 8,936 shares in the last quarter. Finally, Aigen Investment Management LP acquired a new stake in Perspective Therapeutics in the 4th quarter valued at $28,000. Institutional investors own 54.66% of the company’s stock.

Analysts Set New Price Targets

CATX has been the topic of a number of recent research reports. Wedbush reiterated an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a report on Tuesday, May 5th. BTIG Research reaffirmed a “buy” rating on shares of Perspective Therapeutics in a research report on Friday, July 24th. Eight investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $12.62.

View Our Latest Stock Report on CATX

Perspective Therapeutics Company Profile

(Get Free Report)

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.